Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
@hobsy
A great post !
Our test looks amazing !!
hobsy1
Very well said !!! Of course CEO’s have access to insider information !! There are a lot of unhinged delinquents posting on this board ha ha ha
StarKnight
Moz2020
Are you deranged ? First if all it’s not £10 K as you have put it’s just over £11 K !! Secondly they are not free shares !! Trevor Brown has purchased them !! Get your facts right before you post trying to devalue the SP !!
I’ve spoke to Viv a couple of times and found him to be friendly too. As you say obviously he cannot speak about insider information but it is good that he takes the time to speak to us investors
StarKnight
@skippy that is correct but TB obviously does have great confidence in our product ( CX300) for him to be investing in BRH ! Follow the money !!!
Trev has a lot of followers so seeing as he has just bought more shares in addition to the purchase approx a month ago they will all pile in and the SP will move up rapidly !!!
StarKnight
Good morning all
RNS out Trev has bought £11,275 worth of shares at 11.2 p each !!
Link
https://www.londonstockexchange.com/news-article/BRH/director-pdmr-shareholding/15512771
We are getting close to the end of June and news of latest CX300 rapid test to come !!
StarKnight
Hello all
WOW SP just shot up 6.38% to 12.50 p !! Looks like there was a buy of £11.5 Grand !!! Big money pouring in !!! Investors taking positions for a bargain basement share price !!
StarKnight
Patience will be well rewarded !! Don’t worry about sales !! There is a buyer for the sales !! We are moving up gradually now !!
@Armagedon21
I am not paid by BRH !! I have great confidence in Professor Carl Smythe and the CX300 platform !! This device in case you didn’t know is a game changer !!! There is no instant accurate test for sepsis but our device is being developed to change that for the good of mankind !!
If successfully developed it will be in high demand and sold globally !! This will then be a 10 X bagger !!!
StarKnight
Hello all
We had previously hit the bottom for a while but today the SP has risen 4.6% to 12.29 and is in the Top Risers on investing.com !!
There is only one week to go until the end of June by which soon after we should have results from clinical trials on our game changing CX300 rapid test from our 100% owned Paraytec !
I have a feeling the results will be positive and I think investors are already now looking at taking positions in more higher value investments in Braveheart !!!
StarKnight
@Martin1980
Very well said !! The idiots like Halma and Bentster won’t rest until they cause Braveheart to liquidate !! They are paid derampers !!
Oh dear all the ID10T5 are out today !! Of course there are investors here !! Just waiting on big news coming soon then everyone will pile back in !! When this moves it moves fast and will be NT to buy !! Be warned !! You may not ever get shares in BRH at this rock bottom price again !!
StarKnight
Well said Castle !!
These morons are obsessed with us !!
Morning Castley hope you had a good trip to Poland.
Bentster Paraytec is not a dead parrot ! They are taking time to get things right !!
Hello all
Covid-19 infections rise 43% in just over a week in the U.K. !! This is could be the start of a new wave and the fact that it is summer means it is not a winter type variant. This proves that the market for Covid-19 testing has not gone away and the need for a rapid accurate tests is needed now more than ever ! Roll on the release of our CX300
Link
Covid infections up after Platinum Jubilee celebrations https://www.bbc.co.uk/news/health-61839777
StarKnight
Armageddon
Yes you are correct !! Trevor would definitely have known the situation when he bought more shares so I think the market has not factored that in ! The Jewel in our crown is Paraytec which once our game changing CX300 device is globally marketed we will be in for a pot of gold bigger than you’ll find at the end of any rainbow !!
StarKnight
Link to vacancy advertisement
https://www.recruit.net/job/research-assistant-jobs/CD0514026359E080
Extract from todays RNS 16/06/2022 ref Paraytec
Paraytec Limited (Braveheart owns 100% per cent of the company)
Paraytec Limited ("Paraytec") develops high performance specialist detectors for the analytical and life sciences instrumentation markets. In addition, the company has undertaken a programme with the University of Sheffield to develop a rapid test for identifying cancer and pathogens, including viruses.
As reported within our RNS on 15 November 2021, Paraytec has continued to refine the platform technology that underpins its proposed fast, sensitive COVID-19 test. The platform technology (product reference "CX300") comprises a low-cost instrument that utilises intense fluorescent light to detect small specific pathogens or cells in a biological sample.
Although the market for COVID-19 tests has dramatically changed in recent months, the Company believes there will continue to be a significant long-term global market for point-of-care COVID-19 testing. In addition, it is clear that Paraytec's technology platform has the potential for many other applications, and these are primarily the focus of interest in ongoing discussions with potential licensees and acquirers.
Paraytec has recently received ethical and HRA approval to proceed with a clinical study at the Sheffield Teaching Hospitals NHS Foundation Trust. This study will collect specimens from COVID-19 positive participants for up to ten days and monitor the ability of the Paraytec test to follow the course of infection by comparison with the culture of SARS-CoV-2 virus from the specimens. The test performance will also be compared with PCR (polymerase chain reaction) and lateral flow tests. If successful, the Directors believe these results will be a powerful demonstration of the accuracy and uniqueness of the Paraytec test.
Professor Carl Smythe's team has established a CAT 3 laboratory at the University of Sheffield to support the development of the CX300 technology platform. This will allow the research team to study a wide range of pathogens that cause infectious diseases, including COVID-19. Potential acquirers have focused their interest on a range of applications for the CX300, so the Paraytec team will now concentrate on developing multiple tests, including those previously commenced in bladder cancer and bacteraemia that causes sepsis.
So now we are making strides forward to a very exciting future !
Good Luck All
StarKnight
Greetings all
Proof of further development of Paraytec’s CX300 rapid test and expansion of the team at Sheffield University working under the great Professor Carl Smythe has in the last few days advertised for a Research Assistant in Biosensor Development, specifically to work with the Paraytec CX300 rapid test device presumably reference the RNS released today 16/06/2022 which states: -
Paraytec has recently received ethical and HRA approval to proceed with a clinical study at the Sheffield Teaching Hospitals NHS Foundation Trust. This study will collect specimens from COVID-19 positive participants for up to ten days and monitor the ability of the Paraytec test to follow the course of infection by comparison with the culture of SARS-CoV-2 virus from the specimens. The test performance will also be compared with PCR (polymerase chain reaction) and lateral flow tests. If successful, the Directors believe these results will be a powerful demonstration of the accuracy and uniqueness of the Paraytec test.
The job advertisement: -
RESEARCH ASSISTANT IN BIOSENSOR DEVELOPMENT
The University of Sheffield
As Research Assistant in the School of Biosciences you will work on an industry-funded project, directed towards development of a biosensor platform for rapid detection of biomarkers on viruses, bacteria and cells, and to analyse clinical trial samples using that platform for comparison with established gold standard methods. You will be responsible for working closely with external partners using a Paraytec CX300 imaging system, in a team focused on undertaking a medical instrument clinical trial. This post will contribute to translation of basic biology findings into a commercial application. Applicants will have experience in chromatography, fluorimetry and fluid flow-based bioassay development, with laboratory experience in the use of biomolecular imaging. Applicants must have significant laboratory experience in the use and application of biomolecular imaging along with experience working with Paraytec CX300 Imaging technology. Experience in Experience in coronavirus, and/or cell and particle imaging using fluorescence-based techniques are also essential. We're one of the best not-for-profit organisations to work for in the UK. The University's Total Reward Package includes a competitive salary, a generous Pension Scheme and annual leave entitlement, as well as access to a range of learning and development courses to support your personal and professional development. We build teams of people from different heritages and lifestyles from across the world, whose talent and contributions complement each other to greatest effect. We believe diversity in all its forms delivers greater impact through research, teaching and student experience. To find out what makes the University of Sheffield a remarkable place to work, watch this short film: [...] and follow @sheffielduni and @ShefUniJobs on Twitter for more information.
Cont
Thank you Castle :-)
I also like the part about sending the nurse in !!
Can I request she brings a couple of bottles of Brut Champagne ?